Kyung W. Song

Figure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Taselisib-mediated degradation of mutant p110a occurs preferentially at the plasma membrane.

Figure S2 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Activity of GDC-0077 in combination with Palbociclib and/ or Fulvestrant

Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Taselisib and GDC-0077 have increased potency in PIK3CA-mutant cancer cells

Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Taselisib depletes mutant p110a protein through ubiquitin and proteasome mechanism in a dose and time dependent manner

Figure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Taselisib and GDC-0077 induce mutant p110a and not WT p110a degradation

Figure S6 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

RTK activity plays a key role in regulating p110a degradation

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study

Philippe Lucien Bedard, Komal L. Jhaveri, Melissa Kate Accordino, Andrés Cervantes et autres

BACKGROUND: A variety of treatment options continue to be explored in the post-cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) setting for hormone receptor (HR)-positive, HER2-negative locally advanced/metastatic breast cancer (LA/mBC), and optimal sequencing of therapies remains to be determined. This phase 1/1b study examined …

ca, us, es, fr, gb (code pays fourni par la source)

Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human

Laurent Salphati, Jodie Pang, Emile G. Plise, Jonathan Cheong et autres

1. Small molecule inhibitors of the PI3K pathway have been extensively investigated as potential anticancer agents. Among the effectors in this pathway, PI3Kα is the kinase most frequently associated with the development of tumors, through mutations and amplifications of the PIK3CA gene …

us (code pays fourni par la source)

Protective effects of Puriton® on acute pancreatitis

Dong-Uk Kim, Bitna Kweon, Kwang-Ho Kim, Gi‐Sang Bae et autres

Objectives: Puriton® is the electrolyte enriched water consisting of 31 essential minerals from biotite, kaolinite, montmorillonite, serpentine, and clinochlore, and vermiculite. It has been reported to be bactericidal and virucidal. However, the protective effect of Puriton® against acute pancreatitis (AP) has not …

kr, us (code pays fourni par la source)

Androgen receptor and hyaluronan-mediated motility receptor as new molecular targets of baicalein: new molecular mechanisms for its anticancer properties

Mingyue Jiang, Suman Poudel, Kyung W. Song

kr (code pays fourni par la source)

Data from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Abstract PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity …

Data from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Kyung W. Song, Kyle A. Edgar, Emily J. Hanan, Marc A. Hafner et autres

Abstract PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity …